Lp(a) 198 nmol/L in a Vegetarian 28-Year-Old

Presentation

Marathon-running, lean, vegetarian SA male presented for screening after his uncle died suddenly at 41 of MI. BMI 22, BP 116/72, resting heart rate 52. Standard lipids: LDL 104, HDL 58, triglycerides 78, non-HDL 122. ApoB 86. HbA1c 5.2%. By every standard metric, he was a model patient.

Key Finding

On expanded testing: Lp(a) 198 nmol/L (>125 = high risk, >250 = very high risk). LDL particle number 1240 nmol/L (high). Coronary artery calcium score 14 (very abnormal for age 28 — typical score for this age is 0). Apo(a) isoform analysis revealed a small isoform variant strongly associated with CAD in South Asians.

Intervention & Outcome

Lifestyle was already optimized — no further changes possible. Initiated rosuvastatin 5mg (LDL fell to 62, ApoB to 51). Lp(a) is unchanged by statins. Patient was enrolled in a clinical trial of pelacarsen (an antisense oligonucleotide that lowers Lp(a) by ~80%) — the first emerging Lp(a)-specific therapy. He continues annual CAC monitoring.

First Principles

Lp(a) is an LDL particle with apolipoprotein(a) covalently bound. Apo(a) has structural similarity to plasminogen, so Lp(a) competes with the body's clot-dissolving system AND deposits cholesterol in the artery wall AND carries pro-inflammatory oxidized phospholipids. Three pathways of harm in one molecule. Levels are 80-90% genetic, set at birth. South Asian populations carry small-isoform LPA alleles at higher frequency, producing both more particles and more atherogenic ones.